Ionis Pharmaceuticals (IONS) to Release Quarterly Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) will likely be posting its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect Ionis Pharmaceuticals to post earnings of ($1.15) per share and revenue of $131.7480 million for the quarter. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS.Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 11:30 AM ET.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.51. The firm had revenue of $452.00 million during the quarter, compared to the consensus estimate of $270.90 million. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 28.25%.The business’s revenue for the quarter was up 100.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.45) EPS. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ionis Pharmaceuticals Stock Down 2.6%

Shares of NASDAQ:IONS opened at $71.64 on Wednesday. The company has a market capitalization of $11.42 billion, a PE ratio of -38.93 and a beta of 0.33. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.87 and a quick ratio of 2.86. The business has a fifty day moving average price of $59.24 and a two-hundred day moving average price of $44.00. Ionis Pharmaceuticals has a 1 year low of $23.95 and a 1 year high of $74.42.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Royal Bank Of Canada upped their price objective on Ionis Pharmaceuticals from $70.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, September 4th. Raymond James Financial set a $75.00 price target on Ionis Pharmaceuticals and gave the company a “strong-buy” rating in a research report on Monday, September 22nd. The Goldman Sachs Group raised Ionis Pharmaceuticals from a “sell” rating to a “neutral” rating and upped their price target for the company from $45.00 to $65.00 in a research report on Friday, September 26th. Bank of America upped their price target on Ionis Pharmaceuticals from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Tuesday, September 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $78.50.

Insider Activity

In related news, EVP C Frank Bennett sold 33,909 shares of the stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $60.62, for a total transaction of $2,055,563.58. Following the sale, the executive vice president owned 101,570 shares of the company’s stock, valued at approximately $6,157,173.40. This represents a 25.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Brett P. Monia sold 203,814 shares of the stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $60.32, for a total value of $12,294,060.48. Following the sale, the chief executive officer directly owned 180,009 shares in the company, valued at $10,858,142.88. This trade represents a 53.10% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 790,202 shares of company stock worth $48,538,661. 2.71% of the stock is owned by company insiders.

Institutional Trading of Ionis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. lifted its holdings in Ionis Pharmaceuticals by 123.2% during the 2nd quarter. Osaic Holdings Inc. now owns 5,296 shares of the company’s stock worth $209,000 after purchasing an additional 2,923 shares in the last quarter. Franklin Resources Inc. bought a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter valued at about $220,000. Orion Porfolio Solutions LLC bought a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter valued at about $221,000. Focus Partners Wealth boosted its position in shares of Ionis Pharmaceuticals by 30.1% during the 1st quarter. Focus Partners Wealth now owns 9,832 shares of the company’s stock valued at $297,000 after acquiring an additional 2,277 shares during the last quarter. Finally, M&T Bank Corp bought a new stake in shares of Ionis Pharmaceuticals during the 2nd quarter valued at about $303,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.